260 likes | 329 Views
IPF: How to approach the search for new therapies. Peter Bitterman MD Research Director, Lillehei Heart Institute Professor of Medicine University of Minnesota. What is wrong in IPF?. What appears to be normal scar tissue is deposited in the gas exchange surface of the lung.
E N D
IPF: How to approach the search for new therapies Peter Bitterman MD Research Director, Lillehei Heart Institute Professor of Medicine University of Minnesota
What is wrong in IPF? What appears to be normal scar tissue is deposited in the gas exchange surface of the lung University of Minnesota
TREATMENT OPTIONS • Fibroblastic focus • Block formation • Promote elimination
Drug Discovery • Identify Molecular Targets • an “Achilles Heel” • Validate Molecular Targets • Synthesize and Test Compounds University of Minnesota
Pathological Persistence of Cells • In normal healing, fibroblasts choose to die when the wound space is filled – remember what happens to the cells in a tadpole’s tail. • In fibrosis, the fibroblasts hang around. University of Minnesota
Is there another disease where cells appear when and where we don’t want them, and hang around when they shouldn’t? Cancer University of Minnesota
Growth Factor–Growth Factor Receptor1,2,3…i PDGF, TGF, CTGF Adaptor protein1,2,3…j Ras, tyrosine kinase Signal transducer1,2,3…k
Translation Initiation Factor 4F A critical point of convergence
Drug Discovery • Identify Molecular Targets • an “Achilles Heel” • Validate Molecular Targets University of Minnesota
When eIF4F is locked in the on position, new biological properties emerge University of Minnesota
Remove cells from the fibroblastic focus and study in a petri dish • Proliferate • Persist • Produce scar tissue University of Minnesota
Drug Discovery • Identify Molecular Targets • an “Achilles Heel” • Validate Molecular Targets • Synthesize and Test Compounds University of Minnesota
Compounds are designed and synthesized by University of Minnesota Medicinal Chemists
Does it disturb development of the zebrafish embryo? Lead compound cycloheximide
Modify to increase potency Preclinical Testing Patent Transfer to private sector partner R and D Phase 1, 2 and 3 trials Rx University of Minnesota
US taxpayers who support the NIH • Generous alumni and benefactors Thanks to… Vitaly Polunovsky Mark Peterson Svetlana Avdulov J. Carlos Manivel Jose Jesserun Shunan Li Van Michalek David Burrichter David Perlman Douglas Yee Robert Kratzke Nahum Sonenberg (McGill, Montreal) O. Larsson(Karolinska, Stockholm)